Association between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and Tuberculosis
Open Access
- 15 May 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (10) , 1481-1491
- https://doi.org/10.1086/429321
Abstract
Background. The occurrence of acquired rifamycin resistance despite use of directly observed therapy for tuberculosis is associated with advanced humanKeywords
This publication has 17 references indexed in Scilit:
- Tuberculosis Treatment OutcomesAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin UseClinical Infectious Diseases, 2004
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazidThe Lancet, 1999
- Pitfalls in N-acetyltransferase 2 genotypingPharmacogenetics, 1999
- Risk Factors for Rifampin-monoresistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Risk Factors for Rifampin Mono-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Rifampin‐Monoresistant Tuberculosis in New York City, 1993–1994Clinical Infectious Diseases, 1997
- A MODEL BASED ASSESSMENT OF REDISTRIBUTION DEPENDENT ELIMINATION AND BIOAVAILABILITY OF RIFABUTINBiopharmaceutics & Drug Disposition, 1996